APAvadis explores new technological tools to specifically target tumors through the bloodstream.

For this aim, we exploit the morphological and functional diversity of tumor blood vessels compared to normal blood vessels.

By using comparative phage display technology, we select specific peptides that will be further developed for diagnosis and therapy of human cancers.

APAvadis is now developing two main projects, for which the company holds exclusive intellectual property rights.